These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 15663677)

  • 1. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Kendirci M; Miroglu C
    Int J Urol; 2004 Dec; 11(12):1070-7. PubMed ID: 15663677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
    Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
    Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
    Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
    Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
    Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
    Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevalence and prognostic value of serum anti-p53 antibodies in hepatocellular carcinoma. A study of 159 patients].
    Sitruk V; Vaysse J; Chevret S; Ganne-Carrie N; Christidis C; Trinchet J; Beaugrand M
    Gastroenterol Clin Biol; 2000 Dec; 24(12):1159-63. PubMed ID: 11173728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.
    Furihata M; Inoue K; Ohtsuki Y; Hashimoto H; Terao N; Fujita Y
    Cancer Res; 1993 Oct; 53(20):4823-7. PubMed ID: 8402668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma.
    Saffroy R; Lelong JC; Azoulay D; Salvucci M; Reynes M; Bismuth H; Debuire B; Lemoine A
    Br J Cancer; 1999 Feb; 79(3-4):604-10. PubMed ID: 10027337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
    Dekairelle AF; Tombal B; Cosyns JP; Gala JL
    Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma.
    Zigeuner R; Tsybrovskyy O; Ratschek M; Rehak P; Lipsky K; Langner C
    Urology; 2004 Jun; 63(6):1079-83. PubMed ID: 15183954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival.
    Angelopoulou K; Rosen B; Stratis M; Yu H; Solomou M; Diamandis EP
    Cancer; 1996 Nov; 78(10):2146-52. PubMed ID: 8918407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.
    Dalbagni G; Parekh DJ; Ben-Porat L; Potenzoni M; Herr HW; Reuter VE
    BJU Int; 2007 Feb; 99(2):281-5. PubMed ID: 17155984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
    Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
    Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
    Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
    Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
    Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
    Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study.
    Lenner P; Wiklund F; Emdin SO; Arnerlöv C; Eklund C; Hallmans G; Zentgraf H; Dillner J
    Br J Cancer; 1999 Feb; 79(5-6):927-32. PubMed ID: 10070892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma.
    Maehara Y; Kakeji Y; Watanabe A; Baba H; Kusumoto H; Kohnoe S; Sugimachi K
    Cancer; 1999 Jan; 85(2):302-8. PubMed ID: 10023696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum anti-p53 antibodies in gastric cancer patients].
    Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
    Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between serum anti-p53 antibodies and microvessel density in bladder cancer patients.
    Gumus E; Erdamar S; Demirel G; Horasanli K; Ozmen G; Miroglu C
    Urol Int; 2004; 73(3):219-25. PubMed ID: 15539840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of serum p53 antibodies during follow-up after treatment of invasive bladder tumors.
    Gumus E; Demirel G; Tanriverdi O; Horasanli K; Ozmen G; Miroglu C
    Urol Int; 2004; 72(4):292-8. PubMed ID: 15153725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.